Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
详细信息    查看全文
文摘
Recent data in mice have identified de novo ceramide synthesis as the key mediator of hepatic insulin resistance (IR) that in humans characterizes increases in liver fat due to IR (‘Metabolic NAFLD’ but not that due to the I148M gene variant in PNPLA3 (‘PNPLA3 NAFLD’). We determined which bioactive lipids co-segregate with IR in the human liver.

Methods

Liver lipidome was profiled in liver biopsies from 125 subjects that were divided into equally sized groups based on median HOMA-IR (‘High and Low HOMA-IR’, n = 62 and n = 63) or PNPLA3 genotype (PNPLA3148MM/MI, n = 61 vs. PNPLA3148II, n = 64). The subjects were also divided into 4 groups who had either IR, the I148M gene variant, both of the risk factors or neither.

Results

Steatosis and NASH prevalence were similarly increased in ‘High HOMA-IR’ and PNPLA3148MM/MI groups compared to their respective control groups. The ‘High HOMA-IR’ but not the PNPLA3148MM/MI group had features of IR. The liver in ‘High HOMA-IR’ vs. ‘Low HOMA-IR’ was markedly enriched in saturated and monounsaturated triacylglycerols and free fatty acids, dihydroceramides (markers of de novo ceramide synthesis) and ceramides. Markers of other ceramide synthetic pathways were unchanged. In PNPLA3148MM/MIvs. PNPLA3148II, the increase in liver fat was due to polyunsaturated triacylglycerols while other lipids were unchanged. Similar changes were observed when data were analyzed using the 4 subgroups.

Conclusions

Similar increases in liver fat and NASH are associated with a metabolically harmful saturated, ceramide-enriched liver lipidome in ‘Metabolic NAFLD’ but not in ‘PNPLA3 NAFLD’. This difference may explain why metabolic but not PNPLA3 NAFLD increases the risk of type 2 diabetes and cardiovascular disease.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700